Prescription costs in America have been rising for so long, in such a predictable pattern, that most people have quietly adjusted their expectations downward. You check the total at the pharmacy counter, you do the mental math, and sometimes you make a choice no one should have to make. So when the Trump administration launched a government website promising to change that calculus, it was reasonable to be skeptical. The program has been moving fast, though, and the May 2026 expansion into everyday generic medicines is the biggest change yet. Whether the TrumpRx prescription costs on offer actually help you depends on exactly who you are and what you’re taking.
TrumpRx.gov launched in February 2026 as a government-operated website where individuals could purchase certain drugs without using insurance, from participating manufacturers, at discounted prices. The initial launch featured drugs from the first five manufacturers to reach pricing deals with the Trump administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. Then, in May 2026, the program got dramatically larger.
On May 18, 2026, Mark Cuban, who had spent 2024 campaigning for Kamala Harris, stood beside Donald Trump at the White House to announce a major expansion of TrumpRx, adding more than 600 generic medications through Cuban’s Cost Plus Drugs company, alongside Amazon Pharmacy and GoodRx. The political optics were jarring. The policy significance is real, even if the full picture is messier than either side wants to admit.
What TrumpRx Prescription Costs Look Like Now
According to the White House fact sheet on the May 18 expansion, TrumpRx.gov now features more than 600 generic medications, with the stated goal of letting Americans clearly and transparently understand the most competitive cash prices for their medications without insurance middlemen, comparing them against co-pays offered by their insurance company, at local pharmacies and through delivery options offered by private pharmacy programs.
Discounts offered by Amazon Pharmacy, Cost Plus Drugs, and GoodRx are now integrated into TrumpRx.gov. In practical terms, that means the site functions less like a pharmacy and more like a price aggregator: a single place to check what the same drug costs across multiple discount channels. TrumpRx now features two different lists of medications, with “Presidential Deals” for branded medications and “Standard Prices” for generic drugs.
For some drug categories, the headline numbers are striking. The prices for popular GLP-1 medications such as semaglutide (Ozempic and Wegovy) are set to fall from over $1,000 per month to as low as $199 when purchased through the TrumpRx platform, though that $199 price applies to the lowest dosing strength, with the highest strength reaching $499, and the introductory $199 rate applies only for the first two months before increasing to $349. Eli Lilly’s tirzepatide (Zepbound), which currently carries a monthly price tag of over $1,080, is available for approximately $299 through the platform.
Common medications featured on TrumpRx include atorvastatin (a cholesterol medication), clopidogrel (a blood thinner), lisinopril (a medication for high blood pressure), and metformin (a diabetes medication). These are drugs that tens of millions of Americans take every day, which is precisely why the generic expansion matters more than the earlier brand-name-heavy rollout did.
TrumpRx will not have offerings for controlled substances, drugs with FDA-mandated risk evaluation and mitigation strategies, or medications not commonly offered through direct-to-consumer channels. So if the drug you need is a controlled substance or a high-risk specialty medication requiring close monitoring, TrumpRx is not a tool for you.
How the Program Actually Works
TrumpRx does not sell medications directly. Instead, users are asked to print a coupon, which can be used at participating pharmacies. Depending on the manufacturer of a given drug, patients with valid prescriptions can access savings through user-friendly coupons that can be printed or downloaded onto their phones, or through channels set up by the manufacturer and integrated into TrumpRx.gov.
The broader policy goal behind the program is Most-Favored-Nation pricing, a framework that aims to bring American drug prices in line with what similar countries pay. On May 12, 2025, President Trump signed an executive order directing the administration to take numerous actions toward that goal. The TrumpRx platform is the consumer-facing piece of that larger effort. As of late 2025, the Trump administration had reached agreements with five drug manufacturers that included commitments to MFN pricing, investments in U.S. manufacturing, and direct-to-consumer discounts on select drugs via TrumpRx.
The Mark Cuban partnership is worth understanding because it’s not purely symbolic. Cuban founded Cost Plus Drug Company in 2022 around a philosophy of cutting the middlemen out of pharmaceutical pricing, making costs transparent, and passing savings directly to patients. The middlemen he has spent his career disrupting are pharmacy benefit managers (PBMs), the industry that manages prescription drug benefits on behalf of employers and insurance companies, negotiating rebates with drug manufacturers but often retaining those rebates rather than passing the savings to patients. Cost Plus Drugs bypasses PBMs entirely by selling directly to patients at cost plus a small fixed markup, with complete transparency about what every component of the price represents.
According to Fortune’s reporting on the partnership, Cuban told Fortune in October 2025 that he thought the program “could be impactful.” His real concern: “Who has more power and influence over the industry: the PBMs and insurance companies and the contracts they have with brand manufacturers, or the president? That has not been determined yet.” For uninsured or underinsured patients juggling multiple prescriptions, the expanded site does offer genuine help: comparison-shopping across discount providers in one place, where even modest per-drug savings compound over a year.
Who Benefits – and Who Might Not
The drug affordability problem in America is serious. According to CBS News, about 60% of American adults are worried about being able to afford prescription drug costs for themselves or their families, based on a KFF nationwide poll. More than 80% consider the price of prescription drugs unreasonable, and most support increased regulation to lower costs. Americans pay about three times as much as people in other countries for the same prescription drugs.
TrumpRx addresses some corners of that problem more than others. The people most likely to see a real difference are those paying cash for brand-name drugs without insurance, or those on high-deductible health plans who haven’t yet hit their annual threshold. Health experts say the new site may not change what many people actually pay, given that most Americans use insurance to cover prescriptions. The White House specifically mentioned that the drug Xeljanz, a medication used to treat rheumatoid arthritis and other conditions, would be available at a 40% discount through TrumpRx. CBS News’s reporting, however, noted that Xeljanz’s price drop from $2,277 to $1,518 a month would still leave it unaffordable for cash-paying patients.
The deductible question deserves real attention. According to an analysis by the Center for American Progress, TrumpRx coupons cannot be combined with insurance, meaning that roughly 319 million Americans with insurance coverage can benefit only if they pay cash and accept that those payments do not count toward their deductible. Americans paid a record $98 billion out of pocket for prescription drugs in 2024, a 25% increase over five years, all while these structural design limitations were baked into programs like TrumpRx. A patient paying $199 per month through TrumpRx instead of through their plan would spend $2,388 over the year without advancing a dollar toward their deductible threshold. For patients who take multiple medications or have high healthcare needs, that lost progress can increase total long-term spending, outweighing any short-term savings the coupons provide.
The brand-name drug list has drawn scrutiny for a separate reason: most of it features branded drugs competing with far cheaper generic versions from other manufacturers. Cholesterol drug Colestid is listed on TrumpRx at “50% off” for $127.91, while the generic version costs about $17 on the Cost Plus Drugs site. At least 350 branded medications saw price increases at the start of 2026, even as the administration struck individual deals with manufacturers, and that broader list-price creep has not been reversed.
Generics, and Why the May Expansion Changes the Calculation
The earlier version of TrumpRx was easy to dismiss, and not only for political reasons. A website focused on brand-name drugs offers limited help to most Americans because most prescriptions are generics. According to AJMC, approximately 90% of all U.S. prescriptions are for generic drugs, but they account for only a small fraction of total drug spending. That gap explains why branded prices generate outrage, but generics are where the volume lives.
The May 2026 expansion directly addresses this by routing the platform toward the medications most people actually take. The newly added generic medications include commonly prescribed blood pressure drugs, antibiotics, and statins, many priced under $5. That’s a meaningful shift from a site that launched with Ozempic and IVF drugs. By the time of the May 2026 announcement, the platform had already been visited more than 10 million times and had saved Americans more than $400 million on prescription drugs, according to White House-reported figures.
Still, the question of whether TrumpRx is genuinely the best option for any given drug remains open. Prices vary considerably across discount sites and can shift over time, so there’s no single guaranteed first destination. TrumpRx is now a legitimate contender in that comparison. It isn’t automatically the winner.
In a February 2026 commentary, Jeffrey Sonnenfeld, the Yale School of Management Lester Crown Professor of Leadership Practice, wrote along with coauthors that the TrumpRx program doesn’t truly provide meaningful discounts for people who already have insurance coverage. The generic expansion at least partially responds to that critique, but the structural issue around insurance, deductibles, and PBM pricing remains unresolved.
Read More: Trump Administration Pushes Whole Milk, But Health Experts Urge Caution
What to Do With This Right Now
The most honest thing to say about TrumpRx prescription costs is this: the program is more useful than its critics give it credit for, and less transformative than its architects claim. Both things are true at the same time.
If you pay cash for prescriptions because you’re uninsured or underinsured, or if you take a drug that your plan covers poorly, TrumpRx is now genuinely worth checking alongside GoodRx, Cost Plus Drugs, and Amazon Pharmacy. The comparison-shopping work has gotten simpler because the platform now aggregates prices from all three in one place. For blood pressure medication at under $5, or a diabetes drug like metformin, those savings are real.
If you have good insurance and your co-pays are already reasonable, the math gets more complicated fast. Before bypassing your insurance for a TrumpRx coupon price that looks attractive, check whether that purchase counts toward your deductible. For someone managing one simple chronic medication on a generous insurance plan, TrumpRx probably changes nothing. For someone managing several prescriptions with a $2,000 deductible they haven’t hit, or for someone paying out of pocket entirely, the site has real teeth now that generics are included.
The deeper problem, that Americans pay roughly three times what other developed nations pay for the same drugs, that list prices keep rising even while individual deals get made, that 1 in 5 Americans has skipped filling a prescription because of cost, none of that gets resolved by a comparison website, however well designed. What TrumpRx does, particularly with this expansion, is give people one more tool to avoid the worst of those costs while the larger battles over pharmaceutical pricing continue. That’s not nothing. It’s also not the whole answer.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.